Address
Email address
Phone number
Website
https://www.synlab.eeSYNLAB EestiSYNLAB Eesti on suurim meditsiinilabor Eestis, mis tegutseb juba aastast 1995.
Name
SYNLAB Eesti OÜ
Registry code
11107913
VAT number
EE101243708
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
15.04.2005 (19)
Financial year
01.01-31.12
Capital
2 566.00 €
Activity
86902 - Activities of medical laboratories, blood banks, sperm banks and other similar banks
64 880 605 €
14 661 609 €
23%
2 603 €
(estimate is approximate)
38 887 805 €
346
Submitted
No tax arrears
38%
32%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Kaido Beljaev 11.12.1969 (54) | - | Board member | - | |
| Rainar Aamisepp 09.02.1967 (57) | - | Board member | - | |
| Icosagen AS 10565884 | - | - | - | Founder |
| 2020 28.11.2021 | 2021 18.07.2022 | 2022 30.06.2023 | |
|---|---|---|---|
| Total Revenue | 73 640 268 € | 104 462 114 € | 64 880 605 € |
| Net profit (loss) for the period | 27 488 475 € | 38 217 513 € | 14 661 609 € |
| Profit Margin | 37% | 37% | 23% |
| Current Assets | 54 653 396 € | 52 598 779 € | 34 532 878 € |
| Fixed Assets | 11 362 143 € | 11 754 622 € | 10 722 989 € |
| Total Assets | 66 015 539 € | 64 353 401 € | 45 255 867 € |
| Current Liabilities | 10 894 146 € | 11 925 232 € | 6 252 976 € |
| Non Current Liabilities | 21 112 710 € | 201 973 € | 115 086 € |
| Total Liabilities | 32 006 856 € | 12 127 205 € | 6 368 062 € |
| Share Capital | - | - | - |
| Equity | 34 008 683 € | 52 226 196 € | 38 887 805 € |
| Employees | 266 | 381 | 346 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2023 Q4 | 1 035 756.04 € | 1 233 471.04 € | 1 139 214.42 € | 319 |
| 2023 Q3 | 1 202 500.35 € | 1 351 702.9 € | 1 228 389.63 € | 328 |
| 2023 Q2 | 998 347.47 € | 1 548 878.03 € | 1 492 853.31 € | 332 |
| 2023 Q1 | 1 554 220.25 € | 1 398 164.22 € | 1 267 756.52 € | 323 |
| 2022 Q4 | 2 514 421.1 € | 7 910 676.48 € | 1 267 680.41 € | 378 |
| 2022 Q3 | 1 467 629.67 € | 1 462 946.17 € | 1 307 318.61 € | 428 |
| 2022 Q2 | 1 925 435.26 € | 2 030 162.05 € | 1 862 921.66 € | 451 |
| 2022 Q1 | 4 227 671.76 € | 2 747 219.84 € | 2 137 336.08 € | 501 |
| 2021 Q4 | 3 415 907.07 € | 6 928 817.32 € | 1 473 688.61 € | 543 |
| 2021 Q3 | 1 258 519.09 € | 1 622 310.83 € | 1 533 881.96 € | 522 |
| 2021 Q2 | 1 690 107.35 € | 2 495 469.93 € | 2 400 702.45 € | 517 |
| 2021 Q1 | 2 017 817.98 € | 2 499 671 € | 1 496 061.65 € | 492 |
| 2020 Q4 | 5 216 886.61 € | 1 422 516.69 € | 1 344 177.53 € | 439 |
| 2020 Q3 | 2 576 991.73 € | 1 035 953.14 € | 850 404.75 € | 392 |
| 2020 Q2 | 2 005 287.09 € | 1 121 183.02 € | 851 160.56 € | 309 |
| 2020 Q1 | 813 577.94 € | 964 401.23 € | 861 099.14 € | 286 |
